Kura Oncology, Inc.
Pagina dedicata companiei Kura Oncology, Inc. listata cu simbolul US.KURA
Descriere companieModificare
Kura Oncology, Inc. (www.kuraoncology.com) is a clinical-stage biopharmaceutical company. The Company’s segment is engaged in discovery and development of medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and hematologic indications. It is developing KO-539, a small molecule inhibitor of the Lysine K-specific Methyltransferase 2A (KMT2A) interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
Grafic actiuni companieModificare